{
    "clinical_study": {
        "@rank": "3234", 
        "arm_group": [
            {
                "arm_group_label": "Placebo", 
                "arm_group_type": "Placebo Comparator", 
                "description": "once daily orally"
            }, 
            {
                "arm_group_label": "SM-13496 20 -60 mg", 
                "arm_group_type": "Experimental", 
                "description": "once daily orally"
            }, 
            {
                "arm_group_label": "SM-13496 80-120 mg", 
                "arm_group_type": "Experimental", 
                "description": "once daily orally"
            }
        ], 
        "brief_summary": {
            "textblock": "The study evaluates the efficacy and safety of SM-13496 compared with placebo in patients\n      with Bipolar I Depression."
        }, 
        "brief_title": "A Phase III Study of SM-13496 in Patients With Bipolar I Depression.", 
        "completion_date": {
            "#text": "September 2016", 
            "@type": "Anticipated"
        }, 
        "condition": "Bipolar Depression", 
        "condition_browse": {
            "mesh_term": [
                "Bipolar Disorder", 
                "Depression", 
                "Depressive Disorder"
            ]
        }, 
        "detailed_description": {
            "textblock": "The primary objective is to compare the efficacy of SM-13496 (20-60 or 80-120 mg/day)\n      monotherapy with that of placebo in patients with depressive symptoms associated with\n      bipolar I disorder by assessing the change from baseline in the MADRS total score at Week 6."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Patients who were fully informed of and understand the objectives, procedures, and\n             possible benefits and risks of the study and who provided written voluntary consent\n             to participate in the study.\n\n          -  Outpatients aged 18 through 74 years at the time of consent\n\n          -  Patients meets DSM-IV-TR criteria for bipolar I disorder, most recent episode\n             depressed (\u2265 4 weeks and less than 12 months) without psychotic features.\n\n        Exclusion Criteria:\n\n          -  Patients with imminent risk of suicide or injury to self, others, or property.\n\n          -  Patients who had been hospitalized because of a manic or mixed episode within 60 days\n             prior to screening.\n\n          -  Patients who are otherwise considered ineligible for the study by the investigator."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "74 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "501", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "November 4, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01986101", 
            "org_study_id": "D1002001"
        }, 
        "intervention": {
            "arm_group_label": [
                "SM-13496 20 -60 mg", 
                "SM-13496 80-120 mg"
            ], 
            "description": "SM-13496 20-60mg, SM-13496 80-120mg", 
            "intervention_name": "SM-13496 (lurasidone HCl)", 
            "intervention_type": "Drug", 
            "other_name": "Lurasidone"
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "June 1, 2014", 
        "location": [
            {
                "contact": {
                    "last_name": "Principal investigator"
                }, 
                "facility": {
                    "address": {
                        "city": "Beijing", 
                        "country": "China"
                    }, 
                    "name": "China 5 sites"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Principal investigator"
                }, 
                "facility": {
                    "address": {
                        "city": "Tokyo", 
                        "country": "Japan"
                    }, 
                    "name": "Japan 60 sites"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Principal Investigator"
                }, 
                "facility": {
                    "address": {
                        "city": "Kuala Lumpur", 
                        "country": "Malaysia"
                    }, 
                    "name": "Malaysia 4 sites"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Principal Investigator"
                }, 
                "facility": {
                    "address": {
                        "city": "Manila", 
                        "country": "Philippines"
                    }, 
                    "name": "Philippines 5 sites"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Principal investigator"
                }, 
                "facility": {
                    "address": {
                        "city": "Moscow", 
                        "country": "Russian Federation"
                    }, 
                    "name": "Russia 7 sites"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Principal investigator"
                }, 
                "facility": {
                    "address": {
                        "city": "Taipei", 
                        "country": "Taiwan"
                    }, 
                    "name": "Taiwan 4 sites"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Principal Investigator"
                }, 
                "facility": {
                    "address": {
                        "city": "Kiev", 
                        "country": "Ukraine"
                    }, 
                    "name": "Ukraine 7 sites"
                }, 
                "status": "Not yet recruiting"
            }
        ], 
        "location_countries": {
            "country": [
                "China", 
                "Japan", 
                "Malaysia", 
                "Philippines", 
                "Russian Federation", 
                "Taiwan", 
                "Ukraine"
            ]
        }, 
        "number_of_arms": "3", 
        "official_title": "A Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study of SM-13496 for the Treatment of Bipolar I Depression.", 
        "overall_contact": {
            "email": "cc@ds-pharma.co.jp", 
            "last_name": "Dainippon Sumitomo Pharma Co., Ltd."
        }, 
        "overall_official": {
            "affiliation": "Dainippon Sumitomo Pharma", 
            "last_name": "Director, Drug Development Division", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Japan: Pharmaceuticals and Medical Devices Agency", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "August 2016", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Change from baseline in  Montgomery-Asberg Depression Rating Scale (MADRS) total score", 
            "safety_issue": "No", 
            "time_frame": "Baseline, 1, 2, 3, 4, 5 and 6 weeks"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01986101"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Change from baseline in the CGI-BP-S (depression) score.", 
                "safety_issue": "No", 
                "time_frame": "Baseline, 1, 2, 3, 4, 5 and 6 weeks"
            }, 
            {
                "measure": "Change from baseline in the SDS total score", 
                "safety_issue": "No", 
                "time_frame": "Baseline, 1, 2, 3, 4, 5 and 6 weeks"
            }, 
            {
                "measure": "Change from baseline in the YMRS total score", 
                "safety_issue": "No", 
                "time_frame": "Baseline, 1, 2, 3, 4, 5 and 6 weeks"
            }, 
            {
                "measure": "Change from baseline in the HAM-A total score", 
                "safety_issue": "No", 
                "time_frame": "Baseline, 1, 2, 3, 4, 5 and 6 weeks"
            }, 
            {
                "measure": "Incidence of Adverse events (AEs) and Adverse drug reactions (ADRs)", 
                "safety_issue": "Yes", 
                "time_frame": "6 weeks"
            }
        ], 
        "source": "Dainippon Sumitomo Pharma", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Dainippon Sumitomo Pharma", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "November 2013", 
        "study_design": "Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "June 2014"
    }
}